Cargando…

A Rapid Lysostaphin Production Approach and a Convenient Novel Lysostaphin Loaded Nano-emulgel; As a Sustainable Low-Cost Methicillin-Resistant Staphylococcus aureus Combating Platform

Staphylococcus aureus is a Gram-positive pathogen that is capable of infecting almost every organ in the human body. Alarmingly, the rapid emergence of methicillin-resistant S. aureus strains (MRSA) jeopardizes the available treatment options. Herein, we propose sustainable, low-cost production of r...

Descripción completa

Detalles Bibliográficos
Autores principales: Nour El-Din, Hanzada T., Elhosseiny, Noha M., El-Gendy, Mohamed A., Mahmoud, Azza A., Hussein, Manal M. M., Attia, Ahmed S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175171/
https://www.ncbi.nlm.nih.gov/pubmed/32178236
http://dx.doi.org/10.3390/biom10030435
_version_ 1783524775375667200
author Nour El-Din, Hanzada T.
Elhosseiny, Noha M.
El-Gendy, Mohamed A.
Mahmoud, Azza A.
Hussein, Manal M. M.
Attia, Ahmed S.
author_facet Nour El-Din, Hanzada T.
Elhosseiny, Noha M.
El-Gendy, Mohamed A.
Mahmoud, Azza A.
Hussein, Manal M. M.
Attia, Ahmed S.
author_sort Nour El-Din, Hanzada T.
collection PubMed
description Staphylococcus aureus is a Gram-positive pathogen that is capable of infecting almost every organ in the human body. Alarmingly, the rapid emergence of methicillin-resistant S. aureus strains (MRSA) jeopardizes the available treatment options. Herein, we propose sustainable, low-cost production of recombinant lysostaphin (rLST), which is a native bacteriocin destroying the staphylococcal cell wall through its endopeptidase activity. We combined the use of E. coli BL21(DE3)/pET15b, factorial design, and simple Ni-NTA affinity chromatography to optimize rLST production. The enzyme yield was up to 50 mg/L culture, surpassing reported systems. Our rLST demonstrated superlative biofilm combating ability by inhibiting staphylococcal biofilms formation and detachment of already formed biofilms, compared to vancomycin and linezolid. Furthermore, we aimed at developing a novel rLST topical formula targeting staphylococcal skin infections. The phase inversion composition (PIC) method fulfilled this aim with its simple preparatory steps and affordable components. LST nano-emulgel (LNEG) was able to extend active LST release up to 8 h and cure skin infections in a murine skin model. We are introducing a rapid, convenient rLST production platform with an outcome of pure, active rLST incorporated into an effective LNEG formula with scaling-up potential to satisfy the needs of both research and therapeutic purposes.
format Online
Article
Text
id pubmed-7175171
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71751712020-04-28 A Rapid Lysostaphin Production Approach and a Convenient Novel Lysostaphin Loaded Nano-emulgel; As a Sustainable Low-Cost Methicillin-Resistant Staphylococcus aureus Combating Platform Nour El-Din, Hanzada T. Elhosseiny, Noha M. El-Gendy, Mohamed A. Mahmoud, Azza A. Hussein, Manal M. M. Attia, Ahmed S. Biomolecules Article Staphylococcus aureus is a Gram-positive pathogen that is capable of infecting almost every organ in the human body. Alarmingly, the rapid emergence of methicillin-resistant S. aureus strains (MRSA) jeopardizes the available treatment options. Herein, we propose sustainable, low-cost production of recombinant lysostaphin (rLST), which is a native bacteriocin destroying the staphylococcal cell wall through its endopeptidase activity. We combined the use of E. coli BL21(DE3)/pET15b, factorial design, and simple Ni-NTA affinity chromatography to optimize rLST production. The enzyme yield was up to 50 mg/L culture, surpassing reported systems. Our rLST demonstrated superlative biofilm combating ability by inhibiting staphylococcal biofilms formation and detachment of already formed biofilms, compared to vancomycin and linezolid. Furthermore, we aimed at developing a novel rLST topical formula targeting staphylococcal skin infections. The phase inversion composition (PIC) method fulfilled this aim with its simple preparatory steps and affordable components. LST nano-emulgel (LNEG) was able to extend active LST release up to 8 h and cure skin infections in a murine skin model. We are introducing a rapid, convenient rLST production platform with an outcome of pure, active rLST incorporated into an effective LNEG formula with scaling-up potential to satisfy the needs of both research and therapeutic purposes. MDPI 2020-03-12 /pmc/articles/PMC7175171/ /pubmed/32178236 http://dx.doi.org/10.3390/biom10030435 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nour El-Din, Hanzada T.
Elhosseiny, Noha M.
El-Gendy, Mohamed A.
Mahmoud, Azza A.
Hussein, Manal M. M.
Attia, Ahmed S.
A Rapid Lysostaphin Production Approach and a Convenient Novel Lysostaphin Loaded Nano-emulgel; As a Sustainable Low-Cost Methicillin-Resistant Staphylococcus aureus Combating Platform
title A Rapid Lysostaphin Production Approach and a Convenient Novel Lysostaphin Loaded Nano-emulgel; As a Sustainable Low-Cost Methicillin-Resistant Staphylococcus aureus Combating Platform
title_full A Rapid Lysostaphin Production Approach and a Convenient Novel Lysostaphin Loaded Nano-emulgel; As a Sustainable Low-Cost Methicillin-Resistant Staphylococcus aureus Combating Platform
title_fullStr A Rapid Lysostaphin Production Approach and a Convenient Novel Lysostaphin Loaded Nano-emulgel; As a Sustainable Low-Cost Methicillin-Resistant Staphylococcus aureus Combating Platform
title_full_unstemmed A Rapid Lysostaphin Production Approach and a Convenient Novel Lysostaphin Loaded Nano-emulgel; As a Sustainable Low-Cost Methicillin-Resistant Staphylococcus aureus Combating Platform
title_short A Rapid Lysostaphin Production Approach and a Convenient Novel Lysostaphin Loaded Nano-emulgel; As a Sustainable Low-Cost Methicillin-Resistant Staphylococcus aureus Combating Platform
title_sort rapid lysostaphin production approach and a convenient novel lysostaphin loaded nano-emulgel; as a sustainable low-cost methicillin-resistant staphylococcus aureus combating platform
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175171/
https://www.ncbi.nlm.nih.gov/pubmed/32178236
http://dx.doi.org/10.3390/biom10030435
work_keys_str_mv AT noureldinhanzadat arapidlysostaphinproductionapproachandaconvenientnovellysostaphinloadednanoemulgelasasustainablelowcostmethicillinresistantstaphylococcusaureuscombatingplatform
AT elhosseinynoham arapidlysostaphinproductionapproachandaconvenientnovellysostaphinloadednanoemulgelasasustainablelowcostmethicillinresistantstaphylococcusaureuscombatingplatform
AT elgendymohameda arapidlysostaphinproductionapproachandaconvenientnovellysostaphinloadednanoemulgelasasustainablelowcostmethicillinresistantstaphylococcusaureuscombatingplatform
AT mahmoudazzaa arapidlysostaphinproductionapproachandaconvenientnovellysostaphinloadednanoemulgelasasustainablelowcostmethicillinresistantstaphylococcusaureuscombatingplatform
AT husseinmanalmm arapidlysostaphinproductionapproachandaconvenientnovellysostaphinloadednanoemulgelasasustainablelowcostmethicillinresistantstaphylococcusaureuscombatingplatform
AT attiaahmeds arapidlysostaphinproductionapproachandaconvenientnovellysostaphinloadednanoemulgelasasustainablelowcostmethicillinresistantstaphylococcusaureuscombatingplatform
AT noureldinhanzadat rapidlysostaphinproductionapproachandaconvenientnovellysostaphinloadednanoemulgelasasustainablelowcostmethicillinresistantstaphylococcusaureuscombatingplatform
AT elhosseinynoham rapidlysostaphinproductionapproachandaconvenientnovellysostaphinloadednanoemulgelasasustainablelowcostmethicillinresistantstaphylococcusaureuscombatingplatform
AT elgendymohameda rapidlysostaphinproductionapproachandaconvenientnovellysostaphinloadednanoemulgelasasustainablelowcostmethicillinresistantstaphylococcusaureuscombatingplatform
AT mahmoudazzaa rapidlysostaphinproductionapproachandaconvenientnovellysostaphinloadednanoemulgelasasustainablelowcostmethicillinresistantstaphylococcusaureuscombatingplatform
AT husseinmanalmm rapidlysostaphinproductionapproachandaconvenientnovellysostaphinloadednanoemulgelasasustainablelowcostmethicillinresistantstaphylococcusaureuscombatingplatform
AT attiaahmeds rapidlysostaphinproductionapproachandaconvenientnovellysostaphinloadednanoemulgelasasustainablelowcostmethicillinresistantstaphylococcusaureuscombatingplatform